This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
A Guide to Biotech ETF Investing
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Genomics ETFs Surge on CRISPR's Gene Editing Progress
by Sweta Jaiswal, FRM
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
by Sanghamitra Saha
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
ETFs Poised to Benefit from Gene Editing Revolution
by Sweta Jaiswal, FRM
Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
ETFs to Gain From the Booming Genomics Market
by Sweta Jaiswal, FRM
Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE